HealthDay - FRIDAY, May 20 (HealthDay News) -- Edurant (rilpivirine), in combination with other antiretroviral drugs, has been approved by the U.S. Food and Drug Administration to treat HIV-1 infection in adults who haven't taken any prior HIV therapy
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.